Keywords
Mortality
Northern region
Treatment
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To correlate mortality rates due to malignant neoplasm of the stomach with data on the treatment of the disease in the northern region compared to Brazil. Methods: This is a descriptive epidemiological study, based on data collected from the "Panel-oncology" and "Vital statistics" databases of the Department of Informatics of the Sistema Único de Saúde (DATASUS). Results: There is a downward trend in the number of deaths in Brazil, but not at the expense of the northern region, since it tends to remain constant. In addition, it is observed that the duration of treatment in the northern region tends to be longer than 60 days and in Brazil, primarily, 30 days, followed by up to 60 days. Regarding the number of patients treated, there is an upward trend in the number of patients treated in all Brazilian macro-regions, with the exception of the northern region. Conclusion: It was evidenced that although the North is not the macro-region with the highest mortality rates from gastric cancer in Brazil, it has the worst rates of treatment of this neoplasm, in addition to having a deficit of qualified professionals in the oncological area.
References
BARCHI LC, et al. Diretrizes da associação brasileira de câncer gástrico (parte 1): Atualização sobre o diagnóstico, estadiamento, tratamento endoscópico e seguimento. Arquivos brasileiros de cirurgia digestiva [Brazilian archives of digestive surgery], 2020; 33(3).
BARCHI LC, et al. II Consenso Brasileiro de Câncer Gástrico realizado pela Associação Brasileira de Câncer Gástrico. ABCD, 2020; 33.
BESAGIO BP, et al. Câncer gástrico: Revisão de literatura. Brazilian Journal of Health Review, 2021; 4(4); 16439-16450.
BRUM LS, et al. Estudo sobre câncer gástrico, seus fatores de risco e prognósticos: uma revisão integrativa. Revista Eletrônica Acervo Científico, 2021; 38: 9214-9214.
DAS NEVES IS, et al. Análise epidemiológica dos óbitos por câncer de estômago na região Norte do Brasil. Research, Society and Development, 2021; 10(9); 39410917503-39410917503.
GOODWIN CS, et al. "Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., respectively." Int. J. Syst. Bacteriol. 2024; 39: 397-405.
GONÇALVES RP, et al. Fatores de risco do câncer gástrico: Revisão de literatura. Research, Society and Development, 2022; 11(3): 12211324787-12211324787.
HORBUS E e COSTA P. Políticas públicas de saúde para o tratamento do câncer no Brasil e a concentração regional das unidades de tratamento. Espaço e Economia, 2023; 25.
HORA BKS, et al. Análise espacial e temporal da mortalidade por câncer gástrico no Brasil, 2001 a 2020. Research, Society and Development, 2022; 11(14): 550111436909-550111436909.
INCA, 2024. Câncer de estômago. Disponível em: . Acessado em: 5 jan. 2024.
INCA, 2024. Onde tratar pelo SUS. Disponível em: . Acessado em: 5 jan. 2024.
LING Q, et al. Optimal timing of surgery for gastric cancer after neoadjuvant chemotherapy: a systematic review and meta-analysis. World journal of surgical oncology, 2023; 21(1).
MARSHALL BJ, et al. Attempt to fulfil Koch'spostulates for pyloric Campylobacter. Medical Journal of Australia,1985; 142: 436-439.
MOCAN L. Surgical management of gastric cancer: A systematic review. Journal of clinical medicine, 2021; 10(12): 2557.
MACHLOWSKA J, et al. Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies. International journal of molecular sciences, 2020; 21(11): 4012.
MOURA SME, et al. Mortalidade proporcional por câncer de estômago, na região norte, entre 2011 e 2021. Revista Foco (Interdisciplinary Studies Journal), 2023; 16(9).
PEREIRA LS, et al. Perfil clínico-epidemiológico da mortalidade por neoplasia maligna do trato gastrointestinal e sua relação aos fatores de risco no Brasil entre 2000 e 2019. Revista Eletrônica Acervo Saúde, 2023; 23(9): 13094-13094.
RODRIGUES BLP, et al. Perfil clínico-epidemiológico do câncer gástrico no Estado do Pará. Revista Eletrônica Acervo Saúde, 2023; 23(4): 12399-12399.
RUNGE MS e GREGANTI MA. Netter medicina interna. 2ª ed. Elsevier; 2010.
SCHEFFER M, et al. Demografia Médica no Brasil 2018. São Paulo, SP: FMUSP, CFM, Cremesp, 2018; 286.
SCHEFFER M, et al. Demografia Médica no Brasil 2023. São Paulo, SP: FMUSP, AMB, 2023.
SOBRAL GS, et al. Análise do Tempo para Início do Tratamento Oncológico no Brasil: Fatores Demográficos e Relacionados à Neoplasia. Revista Brasileira de Cancerologia, 2022; 68(3).
SUBASINGHE D, et al. Delay in diagnosis to treatment and impact on survival of gastric adenocarcinoma in a low income setting without screening facility. Scientific reports, 2023; 13(1).
SOCIEDADE BRASILEIRA DE ONCOLOGIA CLÍNICA. Quase um terço dos oncologistas clínicos brasileiros estão em SP. Disponível em: . Acessado em: 5 jan. 2024.
TOKUNAGA M, et al. Impact of COVID-19 on gastric cancer treatment in Japanese high-volume centers: a JCOG stomach cancer study group survey. Surgery today, 2022; 52(2); 231–238.
ZIZZO M, et al. Gastrectomy with or without complete omentectomy for advanced gastric cancer: A meta-analysis. Medicina (Kaunas, Lithuania), 2022; 58(9): 1241.